Global Allergy Immunotherapy Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
“Global Allergy Immunotherapy Market” is the title of an upcoming report offered by MarketResearch.Biz. The report contains information and data, and inputs from both primary and secondary data sources, that have been verified and validated by experts in the target market. The report presents a thorough study of revenues, historical data, and information, key developments, and strategies by major players that offer vital insights and perspectives in various scenarios market. Besides critical data and related information, the report includes key trends (both present and future), factors that are driving market growth, factors that are or could be potential restraints to market growth, as well as opportunities that can be leveraged for potential revenue generation in untapped regions and countries. It also covers threats or challenges for existing as well as new entrants in the market. The global allergy immunotherapy market has been segmented on the basis of treatment type, allergy type, distribution channel, as well as regions and countries.
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies such as asthma, insect bites, etc. Immunotherapy involves exposing individuals to larger and larger amounts of allergen in an attempt to change the immune system’s response.
The rising prevalence of allergic disorders across the globe and their respective burdens on the healthcare system is a primary factor that is expected to boost revenue growth of the global allergy immunotherapy market in the years to come. Another factor that is contributing to future revenue growth of this global market is the increasing number of research & development initiatives being undertaken by key industry players for the production of immunotherapy solutions against food allergens. Additionally, rising indoor and outdoor air pollution levels are leading to the increase in the disorders of the respiratory tract such as allergies, asthma, etc., thereby positively contributing to market growth.
Segmentation of the global allergy immunotherapy market is as follows:
In terms of treatment type, the subcutaneous immunotherapy (SCIT) segment accounted for the majority revenue share of the global allergy immunotherapy market in 2019, as it is the most commonly used for of allergen immunotherapy. The sublingual immunotherapy segment is slated to index the fastest rate of revenue growth over the next 10 years.
On the basis of allergy type, the allergic rhinitis segment held the highest number of shares of the global market, and is expected to continue to do so in the years to come.
With respect to distribution channel, the hospital pharmacy segment accounted for the largest number of revenue shares in 2019, due to the increasing number of patients suffering from allergic disorders.
Regional Segmentation and Analysis:
Europe accounted for the majority revenue share of the global allergy immunotherapy market in 2019, and is expected to continue to do so in the foreseeable future. This can be attributed to the large presence of key market players in this region. However, the APAC is expected to register the highest rate of revenue growth over the forecast period, owing to increasing funding for the enhancement of SLIT, as well as the large presence of market players in the emerging Asian markets.
Segmentation of the Global Allergy Immunotherapy Market:
Segmentation by Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
Segmentation by Allergy Type:
- Allergic rhinitis
- Allergic asthma
Segmentation by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Segmentation by Region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- ASIT Biotech
- Mylan N.V.
- Adamis Pharmaceuticals Corporation
- Merck KGaA
- Stallergenes Greer plc
- Allergy Therapeutics Plc
- ALK-Abelló A/S
- DESENTUM OY
- HAL Allergy B.V.
- HollisterStier Allergy
- DBV Technologies SA
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!